Arbutus Biopharma Share Price (NASDAQ: ABUS)

$3.71

▲

0.04

(1.09%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Arbutus Biopharma Stock chart to analyse performance

Arbutus Biopharma stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$3.65
Today's High:$3.71
$3.71
1.62%
Downside
Day's Volatility :1.62%
Upside
0.0%
52 Weeks Low:$2.71
52 Weeks High:$4.73
$3.71
27.09%
Downside
52 Weeks Volatility :42.75%
Upside
21.48%

Arbutus Biopharma Stock Returns

Period	Arbutus Biopharma Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	10.71%	3.6%	0.0%
6 Months	8.77%	-7.7%	0.0%
1 Year	-6.77%	-12.6%	0.0%
3 Years	62.45%	9.5%	-4.7%

Arbutus Biopharma Corporation Key Stats

Check Arbutus Biopharma key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$3.67
Open	$3.68
Today's High	$3.71
Today's Low	$3.65
Market Capitalization	$703.5M
Today's Volume	$765.9K
52 Week High	$4.725
52 Week Low	$2.705
Revenue TTM	$15.4M
EBITDA	$-43.2M
Earnings Per Share (EPS)	$-0.29
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-52.82%

Stock Returns calculator for Arbutus Biopharma Stock including INR - Dollar returns

The Arbutus Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Arbutus Biopharma investment value today

Current value as on today

₹1,01,150

Returns

₹1,150

(+1.15%)

Returns from Arbutus Biopharma Stock

₹4,134 (-4.13%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Arbutus Biopharma Stock

-50%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Arbutus Biopharma Stock from India on INDmoney has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Arbutus Biopharma Corporation

Name
Holdings %
Name
Holdings %
Morgan Stanley - Brokerage Accounts
12.42%
Whitefort Capital Management, LP.
6.94%
BlackRock Inc
6.66%
Two Seas Capital LP
4.94%
Vanguard Group Inc
4.74%
State Street Corp
2.28%

Analyst Recommendation on Arbutus Biopharma Stock

Rating

Trend

Buy

81%Buy

18%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Arbutus Biopharma(by analysts ranked 0 to 5 stars)

Arbutus Biopharma Share Price Target

What analysts predicted

Upside of 41.51%

Target:

$5.25

Current:

$3.71

Arbutus Biopharma share price target is $5.25, a slight Upside of 41.51% compared to current price of $3.71 as per analysts' prediction.

Arbutus Biopharma Stock Insights

Price Movement
In the last 7 days, ABUS stock has moved up by 3.6%
Increasing Revenue
Revenue is up for the last 4 quarters, 1.33M → 10.73M (in $), with an average increase of 36.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -24.52M → 2.52M (in $), with an average increase of 1072.1% per quarter
ABUS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 73.8%
ABUS vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 48.0%
Price to Sales
ForABUS every $1 of sales, investors are willing to pay $45.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Arbutus Biopharma Corporation Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$6.0M	↑ 1.88%
Net Income	$-153.7M	↑ 169.22%
Net Profit Margin	-2.6K%	↓ 1589.56%

	FY20	Y/Y Change
Revenue	$6.9M	↑ 15.02%
Net Income	$-65.2M	↓ 57.58%
Net Profit Margin	-943.17%	↑ 1614.19%

	FY21	Y/Y Change
Revenue	$11.0M	↑ 58.92%
Net Income	$-77.4M	↑ 18.62%
Net Profit Margin	-703.96%	↑ 239.21%

	FY22	Y/Y Change
Revenue	$39.0M	↑ 255.11%
Net Income	$-69.5M	↓ 10.21%
Net Profit Margin	-178.01%	↑ 525.95%

	FY23	Y/Y Change
Revenue	$18.1M	↓ 53.51%
Net Income	$-72.8M	↑ 4.89%
Net Profit Margin	-401.57%	↓ 223.56%

	FY24	Y/Y Change
Revenue	$6.2M	↓ 65.98%
Net Income	$-69.9M	↓ 4.02%
Net Profit Margin	-1.1K%	↓ 731.47%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$1.5M	↓ 28.58%
Net Income	$-17.9M	↓ 7.44%
Net Profit Margin	-1.2K%	↓ 266.45%

	Q2 FY24	Q/Q Change
Revenue	$1.7M	↑ 12.66%
Net Income	$-19.8M	↑ 10.75%
Net Profit Margin	-1.1K%	↑ 19.85%

	Q3 FY24	Q/Q Change
Revenue	$1.3M	↓ 22.42%
Net Income	$-19.7M	↓ 0.4%
Net Profit Margin	-1.5K%	↓ 325.59%

	Q4 FY24	Q/Q Change
Revenue	$1.6M	↑ 17.55%
Net Income	$-12.5M	↓ 36.44%
Net Profit Margin	-796.19%	↑ 676.33%

	Q1 FY25	Q/Q Change
Revenue	$1.8M	↑ 12.07%
Net Income	$-24.5M	↑ 95.71%
Net Profit Margin	-1.4K%	↓ 594.17%

	Q2 FY25	Q/Q Change
Revenue	$10.7M	↑ 508.79%
Net Income	$2.5M	↓ 110.29%
Net Profit Margin	23.49%	↑ 1413.85%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-51.6M	↓ 0.79%

	FY20	Y/Y Change
Profit	$-40.6M	↓ 21.37%

	FY21	Y/Y Change
Profit	$9.2M	↓ 122.76%

	FY22	Y/Y Change
Profit	$37.6M	↑ 307.06%

	FY23	Y/Y Change
Profit	$-55.6M	↓ 247.79%

	FY24	Y/Y Change
Profit	$4.8M	↓ 108.62%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$1.2M	↓ 34.1%

	Q2 FY24	Q/Q Change
Profit	$1.4M	↑ 16.4%

	Q3 FY24	Q/Q Change
Profit	$1.3M	↓ 2.26%

	Q4 FY24	Q/Q Change
Profit	$1.2M	↓ 7.32%

	Q1 FY25	Q/Q Change
Profit	$-7.2M	↓ 679.77%

	Q2 FY25	Q/Q Change
Profit	$10.7M	↓ 249.1%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-71.0M	↑ 4.57%
Investing Cash Flow	$28.3M	↓ 791.17%
Financing Cash Flow	$37.5M	↓ 32.63%

	FY20	Y/Y Change
Operating Cash Flow	$-51.4M	↓ 27.55%
Investing Cash Flow	$-14.9M	↓ 152.61%
Financing Cash Flow	$86.7M	↑ 131.59%

	FY21	Y/Y Change
Operating Cash Flow	$-67.5M	↑ 31.28%
Investing Cash Flow	$-12.7M	↓ 14.96%
Financing Cash Flow	$137.2M	↑ 58.2%

	FY22	Y/Y Change
Operating Cash Flow	$-35.4M	↓ 47.65%
Investing Cash Flow	$-74.9M	↑ 491.12%
Financing Cash Flow	$31.8M	↓ 76.82%

	FY23	Y/Y Change
Operating Cash Flow	$-85.9M	↑ 143.06%
Investing Cash Flow	$50.8M	↓ 167.75%
Financing Cash Flow	$30.6M	↓ 3.67%

	FY24	Y/Y Change
Operating Cash Flow	$-64.9M	↓ 24.54%
Investing Cash Flow	$22.9M	↓ 54.8%
Financing Cash Flow	$52.0M	↑ 69.66%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-19.3M	↑ 18.92%
Investing Cash Flow	$11.7M	↓ 45.97%
Financing Cash Flow	$24.4M	↑ 615.0%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-14.3M	↓ 26.07%
Investing Cash Flow	$9.7M	↓ 17.25%
Financing Cash Flow	$24.0M	↓ 1.66%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-20.7M	↑ 45.36%
Investing Cash Flow	$-12.0M	↓ 223.86%
Financing Cash Flow	$1.8M	↓ 92.61%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-10.3M	↓ 50.26%
Investing Cash Flow	$13.4M	↓ 211.89%
Financing Cash Flow	$1.4M	↓ 19.94%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-13.4M	↑ 29.82%
Investing Cash Flow	$11.3M	↓ 15.38%
Financing Cash Flow	$2.8M	↑ 95.92%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-15.7M	↑ 17.61%
Investing Cash Flow	$15.6M	↑ 37.55%
Financing Cash Flow	$453.0K	↓ 83.73%

Arbutus Biopharma Technicals Summary

Sell

Neutral

Buy

Arbutus Biopharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Arbutus Biopharma Corporation Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Arbutus Biopharma Corporation	13.76%	8.77%	-6.77%	62.45%	34.78%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Arbutus Biopharma Corporation	NA	NA	0.0	-0.25	-0.53	-0.21	NA	0.43
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Arbutus Biopharma Corporation	Buy	$703.5M	34.78%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Organization	Arbutus Biopharma
Employees	44
CEO	Ms. Lindsay Androski J.D., M.B.A.
Industry	Health Technology

Key Management of Arbutus Biopharma Corporation

Name	Title
Ms. Lindsay Androski J.D., M.B.A.	President, CEO & Chairman
Mr. Tuan Nguyen	Chief Financial Officer
Mr. Andrew J. Sung	General Counsel
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.	Corporate Secretary

Important FAQs about investing in ABUS Stock from India :

What is Arbutus Biopharma share price today?

Arbutus Biopharma share price today is $3.71 as on August 30, 2025 at 1:29 am IST at the close of the market. Arbutus Biopharma share today touched a day high of $3.71 and a low of $3.65.

What is the 52 week high and 52 week low for Arbutus Biopharma share?

Arbutus Biopharma share touched a 52 week high of $4.73 and a 52 week low of $2.71. Arbutus Biopharma stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $3.71, lower by 21.48% versus the 52 week high.

How to invest in Arbutus Biopharma Stock (ABUS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Arbutus Biopharma on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arbutus Biopharma Shares that will get you 0.4043 shares as per Arbutus Biopharma share price of $3.71 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Arbutus Biopharma Stock (ABUS) from India?

Indian investors can start investing in Arbutus Biopharma (ABUS) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Arbutus Biopharma stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Arbutus Biopharma share’s latest price of $3.71 as on August 30, 2025 at 1:29 am IST, you will get 2.6954 shares of Arbutus Biopharma. Learn more about fractional shares .

What are the returns that Arbutus Biopharma has given to Indian investors in the last 5 years?

Arbutus Biopharma stock has given 34.78% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?